Supplemental material
Open access
937
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A
Michael Bullanoa U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9961-4576View further author information
, https://orcid.org/0000-0002-9961-4576View further author information
Christina Coolb Precision Value and Health, New York, CA, USAhttps://orcid.org/0000-0003-0086-3474View further author information
, Bob G. Schultza U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAhttps://orcid.org/0000-0002-7023-8378View further author information
, Sneha Durgapalb Precision Value and Health, New York, CA, USAView further author information
, Naomi Sacksb Precision Value and Health, New York, CA, USAhttps://orcid.org/0000-0003-0038-4385View further author information
, Yanmei Liub Precision Value and Health, New York, CA, USAView further author information
, Rebecca Keeb Precision Value and Health, New York, CA, USAView further author information
& Katharine Battb Precision Value and Health, New York, CA, USA;c Department of Internal Medicine, Division of Hematology/Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USAhttps://orcid.org/0000-0003-3672-8741View further author information
show all
Pages 225-230
|
Received 23 Aug 2022, Accepted 16 Dec 2022, Published online: 27 Jan 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.